BioSpace News Archive

BeiGene, Ltd. today announced that the Company will participate in the J.P. Morgan 40th Annual Healthcare Conference on Tuesday, January 11, 2022 at 5:15 p.m. ET.

First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), today announced that it has completed enrollment for Part 2 of the RESERVOIR Phase 2 trial evaluating FW-COV as an outpatient treatment for COVID-19-related gastrointestinal (GI) infections.

CNS Pharmaceuticals, Inc. announced today that it has entered into securities purchase agreements with several institutional and accredited investors.

Sutro Biopharma, Inc. today announced that Bill Newell, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 13, 2022, at 11:15 a.m. ET / 8:15 a.m. PT.

Marengo Therapeutics, Inc. today announced that Zhen Su , M.D., MBA, Chief Executive Officer of Marengo Therapeutics, will present at the 40th Annual J.P. Morgan Health Care Conference.

Anebulo Pharmaceuticals, Inc. announced today that it has appointed Scott L. Anderson as Head of Investor Relations and Public Relations, effective immediately.

JelikaLite Corp, a medical technology company, announced today that the U.S. Food and Drug Administration (FDA) has granted the Breakthrough Device Designation to its Cognilum System.

Anebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022.

Otonomy, Inc. today provided an update on its product pipeline and financial guidance.

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces receipt of guidance from the U.S. Food and Drug Administration (FDA) for the further development of CDI-45205, Cocrystal’s novel SARS-CoV-2 main protease inhibitor as a potential treatment for COVID-19 and its variants via intranasal/pulmonary delivery.